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under the CC BY license (http://creatSummary Objectives: Hemagglutination inhibiting (HI) antibodies correlate with influenza
vaccine protection but their association with protection induced by natural infection has
received less attention and was studied here.
Methods: 940 people from 270 unvaccinated households participated in active ILI surveillance
spanning 3 influenza seasons. At least 494 provided paired blood samples spanning each sea-
son. Influenza infection was confirmed by RT-PCR on nose/throat swabs or serum HI assay con-
version.
Results: Pre-season homologous HI titer was associated with a significantly reduced risk of
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Humansnot H1N1 strains, whether re-circulated (OR 0.90, 95%CI 0.71e1.15), new seasonal (OR 0.86,
95%CI 0.54e1.36) or pandemic H1N1-2009 (OR 0.77, 95%CI 0.40e1.49). The risk of seasonal
and pandemic H1N1 decreased with increasing age (both p < 0.0001), and the risk of pandemic
H1N1 decreased with prior seasonal H1N1 (OR 0.23, 95%CI 0.08e0.62) without inducing measur-
able A/California/04/2009-like titers.
Conclusions: While H1N1 immunity was apparent with increasing age and prior infection, the
effect of pre-season HI titer was at best small, and weak for H1N1 compared to H3N2 and B.
Antibodies targeting non-HI epitopes may have been more important mediators of infection-
neutralizing immunity for H1N1 compared to other subtypes in this setting.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Associat ion. This is an open access art icle under the CC BY l icense (http://
creativecommons.org/licenses/by/3.0/).Background
Each year, seasonal influenza is responsible for three to five
million severe illnesses and 250,000 to 500,000 deaths
worldwide. An accurate and complete understanding of
the mechanisms of immunity to influenza is critical in order
to assess the risk posed by new virus variants and to
optimize immunization strategies. Influenza viruses infect
human cells through the binding of the viral surface hem-
agglutinin (HA) protein to the terminal sialic acid molecules
of glycoproteins and glycolipids expressed on host cell
membranes, and the subsequent fusion of viral and cell
membranes.1 Antibodies directed at targets surrounding
the receptor-binding pocket of the HA can block binding,
and are the best-defined correlate of influenza immunity.
Serum concentrations of antibodies that block receptor
binding are traditionally measured using the hemagglutina-
tion inhibition (HI) assay, and HI titers of between 18 and 40
are associated with a 50% reduction in infection risk.2e8
However, the determinants of immunity to influenza in hu-
mans remain incompletely understood, with HI antibodies
providing only a partial explanation. Indeed, in his seminal
paper describing the protective effect of pre-existing HI an-
tibodies on H3N2 and B infection, Hobson noted that people
with no detectable HI antibodies may be resistant to infec-
tion,3 and it is well recognized that immunity to infection
can span major antigenic variants within a subtype.9e13
When H1N1 re-emerged in 1977 after an absence of 20
years, resistance to infection in people aged over 20 years
was not dependent on HI antibodies6,10 and in 2009, adults
in several Asian countries experienced low rates of
pandemic H1N1 infection despite the virtual absence of
detectable homologous HI antibodies.12e16
Influenza viruses have a high potential for genetic and
antigenic diversity, and influenza epidemiology is charac-
terized by regular epidemics of antigenically distinct
strains.17 Since the binding region of the HA1 protein is a
key target for neutralising antibodies, it is under intense
immune-mediated positive selection pressure, resulting in
the acquisition and retention of amino acid substitutions
that favor escape from immunity. However, the rate of
antigenic evolution of the HA1 differs between subtypes,
with H3N2 evolving faster than H1N1,18,19 an observation
for which there is considerable uncertainty over the mech-
anisms underlying this difference.20
We set out to re-examine the contribution of serum HI
antibody to protection against natural influenza infection inan unvaccinated Vietnamese cohort followed over three
consecutive influenza transmission periods, which included
re-circulating strains, new antigenic variants, and the first
wave of the 2009 H1N1 pandemic.
Participants
The research was approved by the institutional review
board of the National Institute of Hygiene and Epidemi-
ology, Vietnam; the Oxford Tropical Research Ethics Com-
mittee, University of Oxford, UK; and the Ethics Committee
of the London School of Hygiene and Tropical Medicine, UK.
All participants provided written informed consent.
The procedures for selecting the study site and for
selecting and investigating individual participants are
described in detail elsewhere.21 In brief, households in
Thanh Ha commune, Thanh Liem District, Ha Nam Province,
Viet Nam were selected at random. This semi-rural
commune is in the Red-River delta around 60 km from
Hanoi. 940 members of 270 randomly selected households
consented and were enrolled. The cohort is ongoing but
the analysis described here covers three consecutive influ-
enza seasons detected up until April 2010 (Table 1). Influ-
enza seasons were detected via active surveillance for
influenza-like-illness (ILI), defined as a fever > 38 C and
cough or sore throat. Study health workers examined par-
ticipants with ILI and collected nose and throat swabs.
Investigation was enhanced during the first wave of
pandemic H1N1 transmission (SeptembereDecember 2009)
when all members of ILI case households were swabbed
daily for up to 15 days. Blood samples were collected for
serology at baseline in December 2007 and between each
confirmed influenza season (Table 1).
Methods
Virology and serology
Combined nose and throat swabs were assessed by real-
time reverse-transcriptase polymerase chain reaction (RT-
PCR), according to WHO/US CDC protocols (CDC reference
no. I-007-05, Accessed November 30, 2009, at http://www.
who.int/csr/resources/publications/swineflu/CDCRealtime
RTPCR_SwineH1Assay-2009_20090430.pdf). Viruses were
isolated from participants’ swabs and propagated in MDCK
cells. The HA genes of seasonal H1N1 and H3N2 isolates
Table 1 Timing and intensity of influenza transmission in the cohort.
Period Year (months) seasona Subtype Strainb % infected(95% CI)c
Pre-study 2007 H1N1 Solomon Islands/3/06-like e
2007 H3N2 Brisbane/10/2007-like e
2007 B Yamagata Florida/04/2006-like e
Bleed 1 2007 (12) Winter
Season 1 2008 (7e8) Summer H1N1 Brisbane/59/2007-like 7.2 (5.3e9.7)
2008 (8e9) Autumn H3N2 Brisbane/10/2007-like 2.3 (1.3e4.0)
2008 (2,4,6,9,10,12) B Yamagata Florida/04/2006-liked,e 12.6 (10.1e15.6)
Bleed 2 2008 (12) Winter
Season 2 2009 (4) Spring H1N1 Brisbane/59/2007-like 8.6 (6.6e11.0)
2009 (4e6) Spring H3N2 Perth/16/2009-like 13.1 (10.7e16.0)
2009 (4) Spring B Victoria Cambodia/30/2011-likee 10.5 (8.3e13.1)
Bleed 3 2009 (6) Summer
Season 3 2009 (9e12) Autumn H1N1 California/04/2009-like 18.2 (15.3e21.5)
Bleed 4 2010 (4) Spring
a Months (January Z 1 e December Z 12) when influenza virus RNA was detected in swabs by RT-PCR.
b Strain designation is based on National Influenza Surveillance programme data from Northern Vietnam coordinated by the National
Influenza Center at the National Institute of Hygiene and Epidemiology. Strains considered to be antigenically distinct compared to those
circulating previously are shown in bold.
c The number of participants assessed is shown in Table 2.
d This strain started to circulate just prior to study commencement and continued to circulate during the study.
e Six influenza B strains were isolated in S1 and belonged to the Yamagata lineage whereas a single strain was isolated in S2 and be-
longed to the Victoria lineage (Table S1).
Correlates of influenza immunity 189were amplified and DNA sequencing performed using a 3100
genetic analyzer and BigDye Terminator Mix v3.0 (Applied
Biosystems Inc.). Genome sequences representing vaccine
strains and some with >93% identity to isolates sequenced
in this study were downloaded from the NCBI Influenza Vi-
rus Resource (http://www.ncbi.nlm.nih.gov/genomes/
FLU/FLU.html). Alignment of multiple sequences was per-
formed by the ClustalW method.22 Phylogenetic trees
were constructed using the maximum likelihood and
neighbor-joining methods in the PHYLIP software package
(version 3.66, University of Washington, Seattle, WA).23
Seasonal H3N2 and B isolates also underwent thorough anti-
genic characterization by the WHO Collaborating Center for
Reference and Research in Influenza in Melbourne,
Australia. One H1N1 isolate from 2008 to 2 from 2009
were assessed in HI assay with seasonal H1N1 reference
sera provided in the 2010e2011 WHO Influenza Reagent
Kit For Identification of Influenza Isolates (produced and
distributed by: WHO Collaborating Center for Surveillance,
Epidemiology and Control of Influenza, Centers for Disease
Control and Prevention, Atlanta, Georgia 30333, U.S.A).
Venous blood was collected into heparin vacutainers for
the first two collection times and into serum vacutainers for
the last two collection times. Plasma or sera was separated
within 4 h and stored at 20 C. Paired plasma/sera were
tested in hemagglutination inhibition (HI) assay as previ-
ously described.21 Seasonal influenza H1N1 and H3N2 vi-
ruses isolated from participants’ swabs and propagated in
MDCK cells were used for HI assay with serum pairs spanning
season 1. The same H1N1 virus was used to assess season 2
plasma whereas the H3N2 virus used (TX265) was isolated
from a patient presenting in Hanoi in the same season,
and propagated in embryonated hen’s eggs. This virus was
genetically and antigenically similar to viruses isolated
from participants’ swabs (Supplementary Information). Asingle influenza B virus isolated from a participant during
2008, and propagated in MDCK cells was used to assess
serum for both the first and second seasons. The virus had
a titer of 320 with B/Wisconsin/1/2010 (Yamagata) refer-
ence antisera and of <10 with B/Brisbane/60/2008 (Victo-
ria) antisera. A reference antigen supplied by WHO (A/
California/7/2009(H1N1)-like) was used to assess season
3/pandemic plasma. The HI titer was read as the reciprocal
of the highest serum dilution causing complete inhibition of
agglutination, partial agglutination was not scored as inhi-
bition of agglutination. If there was no inhibition of HI at
the highest serum concentration (1:10 dilution) the titer
was designated as 5. Only one sample had a titer >1280
and this was not adjusted.Definitions and analysis
‘Influenza infection’ was defined as either the detection of
influenza RNA in a swab sample by RT-PCR or a four fold or
greater rise in HI titer, with a second titer of at least 40.
Participants were excluded from analysis of each season
if they were not present for ILI surveillance during the
periods of confirmed influenza transmission or if paired-
plasma were not collected. Additionally, participants were
excluded from the analysis of effect of infection in one
season on infection in subsequent season if they had not
been available or fully assessed for infection in both
seasons.
The risk of an infection was modeled as depending on
the (log2-transformed) pre-season titer using a marginal
logistic regression model, which takes into account poten-
tial household clustering. Unadjusted titer effects and titer
effects adjusted for age (modeled as a natural cubic spline
with 3 degrees of freedom and knots at 10 and 20 years)
190 A. Fox et al.were calculated. We also tested for potential non-linear
effects of the log2-titer on outcome by additionally
including a quadratic term into the model and for titereage
interactions. The risk of infection was also modeled as
depending on infection in the preceding season with each
strain that did not induce HI antibodies (i.e. prior heterol-
ogous infections). As above, marginal logistic regression
was used to account for potential household clustering and
results adjusted for effects of age and pre-season HI titer.
Statistical analyses were performed with the statistical
software R version 2.15.0 (R foundation for Statistical
Computing, Vienna, Austria) and the companion R package
geepack version 1.1-6.
Results
Participants and infections
A detailed description of the cohort and of the infections
and illnesses detected has been presented previously.21 In
brief, 940 individuals were studied for three consecutive
influenza seasons, from December 2007 through April
2010, resulting in 1793 person-seasons of influenza surveil-
lance. The age of participants ranged from <1 to 90 years
and none had ever received influenza vaccination. Weekly
active surveillance for episodes of influenza-like illness
(ILI) was conducted, and a nose swab and throat swab ob-
tained from ILI cases for the detection of influenza RNA
by reverse transcription polymerase chain reaction (RT-
PCR). Participants who were 5 years of age or older at
the time of sampling were asked to provide blood at
recruitment and after each peak in confirmed case detec-
tion for paired serology. Age- and sex-standardized esti-
mates of the risk of influenza infection and illness per
season in persons 5 years of age or older were reported
previously.21
Three influenza seasons were identified in this study
period (Table 1). The number of people that provided blood
samples spanning each season, the numbers infected as
determined by serology and RT-PCR, and their age distribu-
tion is shown as supplementary information (Fig. S1). Males,
and participants aged less than 5 or in their late teens were
under-represented in the group that could be analyzed
(Fig. S1). Genetic and antigenic characterization of the vi-
ruses isolated and used for serology is shown in supplemen-
tary information (Fig. S2 and Table S1). The H1N1 viruses
isolated in season one (S1) in 2008 were A/Brisbane/59/
2007-like, and B virus isolates were of the B-Yamagata-line-
age and were B/Florida/4/2006-like, representing strains
that were antigenically distinct from the pre-study season.
The H3N2 viruses isolated in S1 were antigenically A/Bris-
bane/10/2007-like, as in the pre-study season, and caused
few infections. The H3N2 viruses isolated in the second sea-
son (S2) in Spring 2009 were antigenically distinct A/Perth/
16/2009-like strains, and caused the highest incidence of
infection, whereas two H1N1 isolates were similar to the
S1 isolate. HI titers with WHO reference sera against sea-
sonal H1N1 were 1280 against the 2008 H1N1 isolate and
640 against both 2009 H1N1 isolates. The only B virus iso-
lated in 2009 belonged to the B-Victoria lineage, and the
National Influenza surveillance system identified a shift inB-lineage predominance from Yamagata to Victoria in
2009. However serology was only performed with a Yama-
gata lineage virus. The third season (S3) in Autumn 2009,
was caused by the pandemic H1N1 2009 strain (A/Califor-
nia/04/2009), which resulted in a high incidence of infec-
tion compared to individual seasonal strains.
It was not feasible to collect swabs from all cohort
participants weekly; hence infections were also identified
by HI antibody seroconversion. As in our previous report,
seroconversion was defined as at least a 4-fold rise in titer
with a post-season titer of at least 40.21 We have recently
reported that the pattern of 2-fold increases in HI titer
cannot be fully explained by assay variability, and that a
reliance on four-fold titer increases to define infection
may under estimate the true incidence of infection.24 How-
ever, since it is not possible to adjust for assay variability in
an individual level analysis we did not apply a 2-fold
definition.
The seroconversion rate amongst virologically confirmed
cases indicated that the sensitivity of serology was high for
detecting H3N2 infection (9/9, 100%), but only 66% (23/35)
for H1N1 infection (Supplementary, Table S2). Post-
infection geometric mean HI titers were significantly higher
for virologically confirmed H3N2 cases compared to H1N1
cases (p < 0.001) with values of 218 (95%CI 113e421) and
40 (95%CI 26e62), respectively. A number of participants
with virologically confirmed H1N1 that did not seroconvert,
according to our pre-defined criteria, exhibited a 2-fold in-
crease in titer or a 4-fold increase from 5 to 20.Detection of HI antibody in pre-season plasma and
effect on homosubtypic infection
The proportion of participants with HI antibody titers of 20
or more in pre-season plasma ranged between 11% and 48%
for seasonal influenza strains but was only 2.3% for
pandemic A/California/04/2009-like virus.
The effect of pre-season serum/plasma HI titer on
subsequent homosubtypic infection was investigated for
each subtype and season. Log2 titers were modeled to
affect the log-odds of the risk of infection linearly with
adjustment for age (Table 2). There was a significant linear
effect of HI titer on the risk of infection for H3N2 in S2 and
influenza B (Yamagata lineage) in S1 and S2 but not for
H1N1 in S1, S2 or S3. There was no evidence for a non-
linear (quadratic) association for any of the analyses (all
p > 0.1), except for H1N1 in S2 (p Z 0.01), where there
was evidence that titers  80 may decrease the risk of
infection.
After adjusting for HI titer, age was independently
associated with decreasing risk of infection for H1N1 in S1
(p Z 0.08), S2 (p < 0.0001), and pandemic S3 (p < 0.0001)
and for H3N2 in S2 (pZ 0.03), however there was no signif-
icant age effect for influenza B (Yamagata lineage) (p > 0.6
in S1 and S2). This is concordant with age effects, unad-
justed for titer, discussed in detail in our previous report.21
There was no evidence for titereage interactions (all
p > 0.3), except for H3N2 in S1 (p Z 0.06).
To examine whether the relation between HI titer and
protection is significantly different for H1N1 compared to
H3N2 and B, the association between infection with a strain
Table 2 Pre-season HI titer detection and effect on homosubtypic infection.
Season Infecting/serology strain Pre-season
HI titer
n infected/n
with titer (%)
OR for each 2-fold
titer increase [95% CI]
OR for each 2-fold titer
increase, adjusted for
age [95% CI]
1 H1N1 <Z10 35/486 (7.2) 0.95 [0.63e1.43]; 0.86 [0.54e1.36];
A/Brisbane/59/2007-like 20 3/36 (8.3) p Z 0.79 p Z 0.52
40 2/21 (9.5)
80 0/5 (0.0)
1 H3N2 <Z10 9/359 (2.5) 0.91 [0.71e1.17]; 0.75 [0.48e1.16];
A/Brisbane/10/2007-like 20 1/73 (1.4) p Z 0.45 p Z 0.19
40 2/56 (3.6)
80 0/60 (0.0)
1 B/Florida/04/2006-like <Z10 53/285 (18.6) 0.65 [0.53e0.79]; 0.65 [0.54e0.80];
20 8/121 (6.6) p < 0.0001 p < 0.0001
40 8/67 (11.9)
80 1/75 (1.3)
2 H1N1 <Z10 38/410 (9.3) 1.10 [0.89e1.36]; 0.90 [0.71e1.15];
A/Brisbane/59/2007-like 20 7/51 (13.7) p Z 0.39* p Z 0.40*
40 2/19 (10.5)
80 0/14 (0.0)
2 H3N2 <Z10 67/404 (16.6) 0.69 (0.52e0.90); 0.61 [0.44e0.84];
A/Perth/16/2009-like 20 2/48 (4.2) p Z 0.008 p Z 0.002
40 2/23 (8.7)
80 0/19 (0.0)
2 B/Florida/04/2006-like <Z10 47/302 (15.6) 0.79 [0.65e0.97]; 0.78 [0.63e0.97];
20 6/93 (6.5) p Z 0.03 p Z 0.02
40 4/73 (5.5)
80 2/26 (7.7)
3 H1N1 <Z10 103/526 (19.6) 0.54 [0.27e1.10]; 0.77 [0.40e1.49];
A/California/04/09-like 20 1/14 (7.1) p Z 0.09 p Z 0.43
Note that titers are modeled as a continuous variable and do not use the categorization shown, therefore 0 values in a category do not
prevent analysis.
*/** Test for non-linear (quadratic) effect of (log2-) titer on outcome: p < 0.05 (*).
Between-strain comparisons of titer effects on the risk of infection (not adjusted for age):
- H1 vs. H3: p Z 0.07 (using data from all 3 seasons) [p Z 0.87 (season 1), p Z 0.008 (season 2)].
- H1 vs. B: p Z 0.003 (using data from all 3 seasons) [p Z 0.10 (season 1), p Z 0.03 (season 2)].
Between-strain comparisons of titer effects on the risk of infection (adjusted for age):
- H1 vs. H3: p Z 0.03 (using data from all 3 seasons) [p Z 0.82 (season 1), p Z 0.006 (season 2)].
- H1 vs. B: p Z 0.02 (using data from all 3 seasons) [p Z 0.18 (season 1), p Z 0.09 (season 2)].
Correlates of influenza immunity 191and the HI titer against that strain was modeled with an
interaction with other strains. The effect of HI titer was
significantly different for H3N2 and B versus H1N1, but this
was mainly due to differences during season 2 (Table 2).
The effect of including titer rises from 5 (<10) to 20 in
the definition of seroconversion and hence infection was
examined (Supplementary, Table S3). All associations that
were significant using the original definition of infection re-
mained significant. In addition, unadjusted and age-
adjusted associations between pre-season H3N2 titer and
infection in season 1 were significant with the new defini-
tion, and other significant effect sizes were greater, re-
flecting increases in the numbers defined as infected
amongst participants whose pre-season titer was 5. The ef-
fects of pre-season titer on homologous H1N1 strain infec-
tion remained insignificant with the exception of H1N1 in
S2, which was significant only after adjusting for age. There
was no evidence for titereage interactions.
The number of participants with ILI confirmed as
influenza was small (Fig. S1), and associations between HItiter and illness amongst those infected were not signifi-
cant, although there was trend for participants who devel-
oped ILI after H3N2 infection in season 2 to have lower pre-
season titers (Fig. S3).Effect of prior heterologous infection
To further investigate whether non-HI antibodies
contribute to protection against infection we assessed the
effect of infection in S1 or S2 on infection in S2 or S3
respectively, when the first infection did not induce HI
antibodies to the second infection (Table 3). This analysis
was limited to comparisons across different subtypes with
the exception of H1N1 in S2, which was not associated
with production of HI antibodies to pandemic H1N1 in S3
(pZ 0.921). Associations between influenza A and B infec-
tions were investigated to verify whether effects reflect
adaptive antibody responses as opposed to non-specific
mechanisms. For S2, there was no detectable effect of
Table 3 Effect of previous infection with a different strain on current infection, adjusted for pre-season HI titer and age.
Outcome Variable n infected/included (%) OR for prior infection [95% CI]
Season 2 e H3 season 1
H1N1 e not infected 47/482 (9.8) 0.18 [0.01e3.09]; p Z 0.24a
A/Brisbane/59/2007 e infected 0/12 (0.0)
B season 1
e not infected 41/429 (9.6) 0.89 [0.32e2.43]; p Z 0.81
e infected 6/65 (9.2)
Season 2 e H1N1 season 1
H3N2 e not infected 68/460 (14.8) 0.48 [0.15e1.55]; p Z 0.22
A/Perth/16/2009b e infected 3/34 (8.8)
B season 1
e not infected 61/429 (14.2) 1.08 [0.52e2.22]; p Z 0.84
e infected 10/65 (15.4)
Season 2 e H1 season 1
B/Florida/04/2006b e not infected 57/460 (12.4) 0.39 [0.09e1.73]; p Z 0.22
e infected 2/34 (5.9)
H3 season 1
e not infected 59/482 (12.2) 0.16 [0.01e2.75]; p Z 0.21a
e infected 0/12 (0.0)
Season 3 e H1 season 2
H1N1 e not infected 97/491 (19.8) 0.23 [0.08e0.62]; p Z 0.004c
A/California/04/09 e infected 5/49 (10.2)
H3 season 2
e not infected 87/469 (18.6) 0.88 [0.45e1.74]; p Z 0.72
e infected 15/71 (21.1)
B season 2
e not infected 85/483 (17.6) 2.40 [1.14e5.05]; p Z 0.02c
e infected 17/57 (29.8)
a Based on Bayesian logistic regression and ignoring potential household clustering to cope with separation.
b Pre-season titers remain significant for S2eH3 and S2eB after adjusting for prior infection with a different serotype (and age): all
p < 0.05.
c Both p-values remain significant if H1 season 2 and B season 2 are included jointly into the logistic model (pZ 0.002 for H1 season 2,
pZ 0.01 for B season 2). p-values for analysis without adjustment for age and pre-season titer: 0.11 (H1 season 2) and 0.05 (B season 2).
192 A. Fox et al.prior H1N1 infection on subsequent H3N2 infection or vice
versa but the numbers infected were small and confidence
intervals were large, particularly for the effects of H3N2.
However, infection with H1N1 in S2 was associated with a
clear reduction in the risk of pandemic H1N1 infection in
S3, whereas B (Yamagata) had the opposite effect and
H3N2 had no significant effect. There was no similar effect
of B in S1 on H1N1 in S2 despite similar sample sizes. The
effects of H1N1 and B infection in S2 on pandemic H1N1
infection in S3 were maintained after adjusting for age
and pre-season HI titer, and when both prior H1N1 and B
were included together in the same model.Discussion
In subjects whose influenza immunity has been shaped by
prior natural infection without vaccination, protection
against infection was significantly associated with homolo-
gous HI titer for H3N2 and B Yamagata lineage but not for
H1N1. However, protection against H1N1 infection was
associated with increasing age, and protection against
pandemic H1N1 was also associated with prior confirmed
seasonal H1N1 infection, even though HI antibodies were
rarely detected. It was also clear that HI antibodies werenot always induced following H1N1 infection and titers
induced were low relative to H3N2 infection. The lower
levels of H1N1 HI seroconversion following virologically
confirmed infection means that we may have underesti-
mated the proportion of participants that were H1N1
infected, and this potential under-ascertainment of in-
fections would be concentrated amongst those with low
baseline titers. This could be one factor that decreases the
likelihood of detecting a significant protective effect of
H1N1 HI titers, but also indicates a difference between the
subtypes with respect to HI antibody. There was some
indication that high HI titers (80) protected against H1N1
in season 2, whereas results for linear effects of HI
antibodies on H1N1 were consistent for three transmission
periods including a re-circulated, a newly drifted, and a
shifted strain. Confidence intervals, especially for season 2,
were sufficiently narrow to rule out a large linear effect of
HI titer.
The findings presented here must be reconciled with the
long-standing view that HI titers correlate with
protection,3,5,25e27 and with evidence that HI antibodies
block virus binding to host cell membrane receptors, corre-
late with neutralization in tissue and egg culture, and
transfer protection in mice.3,5,28 An important factor to
consider is that the challenge studies that first established
Correlates of influenza immunity 193a correlation between HI titer and protection did not
include H1N1 strains3,27,29 and many subsequent studies
have looked at HI antibodies induced by inactivated subunit
vaccines given intramuscularly rather than by natural infec-
tion via the respiratory route.7,25,26,30 There is substantial
evidence that inactivated vaccine and live virus infections
induce different antibodies. It is particularly well estab-
lished that intranasal live attenuated influenza vaccines
(LAIV) provide equivalent protection to inactivated vaccine
although HI titers are invariably lower and underestimate
efficacy.7,29,31e35 Neutralizing antibody titer, influenza spe-
cific airway IgA, influenza specific IgG þ B cell frequency, or
combinations of these factors correlate better with LAIV
efficacy.33e36 Nevertheless, a number of natural infection
cohorts have demonstrated correlations between homolo-
gous HI titers and protection against H1N1 infection. In
some of these studies participants had very little prior
exposure to natural H1N1 infection, as in a study of board-
ing school students just 3 years after H1N1 re-emerged.37 In
others immunity may have been shaped by vaccination, as
in two cohort studies that enrolled adults soon after the
2009 pandemic started.38,39 At least 10% of participants in
these cohorts had received seasonal influenza vaccine,
and the proportions with detectable pandemic H1N1 HI
antibody at baseline was at least 2-fold higher than in the
present study. Another study found a significant effect of
baseline titer on pandemic H1N1 infection in adults that
had not had influenza vaccine in the preceding season of
whom 10e15% had already been infected at baseline.40 In
the present study cohort participants had never been vacci-
nated against influenza, and only 6% had a detectable
pandemic H1N1 antibody titer at baseline, most of whom
has titers of just 10. This indicates that the association be-
tween HI antibodies and protection against H1N1 may vary
depending on the population or strains involved and timing
of investigation in relation to antigenic drift or shift.
Numerous other studies of the 1977 and 2009 H1N1
pandemics found that infection risk was associated with
age independent of HI antibody titers, and suggest that this
phenomenon is due to broadly neutralizing, non-HI anti-
bodies.6,11e13,38,39,41e43 We therefore reconcile our results
by hypothesizing that while HI antibodies can neutralize
H1N1 virus and provide immunity against infection, they
are not always the only or indeed the dominant type of
antibody mediating this protection.
This study has several limitations. We do not know how
HI titers in pre-season plasma relate to titers at the time of
influenza transmission because HI titers decay, particularly
in the first six months after infection.10 We have previously
reported that HI titer decay was most common during the
first season when the interval between pre- and post-
season sample collection was longest.24 Over this season
H3N2 titers decayed in 30% of participants and B titers in
11%, consistent with circulation of these strains just prior
to collection of baseline plasma. In contrast, H1N1 HI titers
decayed in only 1% of participants during each of the 3 sea-
sons assessed.24 Therefore antibody titer decay cannot
explain the observed differences between H1N1, H3N2,
and B. We cannot rule out the possibility that HA-
directed antibodies that block H1N1 virus binding to respi-
ratory epithelial cells are present but not detected by the
HI assay with red blood cells. However, results wereconsistent for two different H1N1 and H3N2 strains; all HI
assays were performed using the same protocol and for sea-
son 2 all tests were performed with the same batch of red
blood cells; and our protocol was validated by testing sub-
sets of sera in other internal and external laboratories. HI
titers in serum and plasma correlate well with more than
80% agreement for seroconversion, but plasma titers are
lower.44 Therefore, pre-season 1 and 2 titers may be under-
estimated, but effects will be the same across subtypes.
Although we did not find a significant effect of baseline
HI titer on H3N2 infection during season 1, there were a
very small number of H3N2 infections in that season
(n Z 12) and effects were significant if we expanded the
definition of infection to include four-fold changes in anti-
body level from titer 5 to 20. Finally, we did not perform
serology to identify B Victoria lineage infections so do not
know if there was an effect of HI titer on infection for
this lineage. It will be important to examine effects of
past infection with one lineage on infection with the other
lineage in future.
Our findings indicate that in this unvaccinated popula-
tion prior natural influenza H1N1 infections induced immu-
nity against infection with new drifted and novel strains,
which did not appear to be reliant on HI antibodies.
Further, this putative non-HI neutralizing activity may be
a predominant source of H1N1 neutralization. A similar
inference was drawn from the English physicians study
(1973e1978), which concluded that “factors other than
strain-specific antibodies may be responsible in protecting
against influenza during a period of drift”.45 In ferrets,
infection with a sequence of antigenically distinct seasonal
H1N1 viruses elicits antibodies that protect against novel
2009 H1N1, whereas no single seasonal H1N1 virus assessed
elicited cross-protective antibody.46 Ferret studies using
shifted challenge strains may help to determine whether
the breadth of protection, or cross-neutralization, induced
by sequential variant strain infections is greater for H1N1
than for H3N2. Repeated infection with different live virus
strains preferentially induces HA cross-reactive anti-
bodies,10 and we hypothesize that these include pan-
H1N1 neutralizing antibodies. One of the best-described
targets for cross-neutralizing antibodies is the membrane-
proximal region of HA that facilitates fusion; this region is
conserved amongst H1N1 strains but distinct from
H3N2.1,47 Antibodies that inhibit fusion are technically diffi-
cult to detect,48 but have been found amongst broadly-
neutralizing monoclonal antibodies raised in mice49,50 and
in human phage-display antibody libraries.1,47,51e53 It will
also be important to examine neuraminidase inhibiting
(NI) antibodies, which have been associated with protec-
tion against both infection and illness independent of ef-
fects of HI antibodies.40 Recent studies also describe the
detection of cross-reactive antibodies that trigger NK cell
activation and in vitro elimination of influenza-infected
cells in people lacking HI antibodies.54
If the phenomenon observed in this study is replicable
and widespread it may account for differences in the rate
of antigenic evolution of the HA1 region of H1N1 compared
to H3N2, as evidenced by nineteen drift variants identified
for H3N2 over a 29 year period but only 6 for H1N1.18 Spe-
cifically, if the contribution of HI antibodies relative to non-
HI antibodies to virus neutralization is less for H1N1 than for
194 A. Fox et al.H3N2, then the selective advantage of mutations within HI
antibody binding sites will be less, and antigenic evolution
will be slower. This hypothesis is consistent with the lower
post-infection geometric mean HI titers we observed
amongst RT-PCR confirmed H1N1 cases compared to H3N2
cases, with similar findings reported for the comparison of
live attenuated H1N1 and H3N2 vaccines55 and for studies
of vaccine responses in the elderly.56 Non-HI antibodies
could prevent HI antibody induction either by enhancing vi-
rus clearance or by competing for antigen. It will be impor-
tant to confirm whether non-HI neutralizing antibodies
account for the absence of a detectable protective effect
of baseline H1N1 HI antibodies in our cohort.
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